LIMES Schlosskliniken (LIK) H2 2024 earnings summary

Executive summary

• Total revenue remained stable at EUR 38.0m for 2024, matching the previous year.

• Patient days increased by 3% to 48,021, reflecting higher occupancy in several clinics.

• Clinic start-up costs negatively impacted 2024 results by EUR 430k.

Financial highlights

• EBITDA declined by 6% to EUR 7.3m year-over-year.

• EBIT dropped by 17% to EUR 4.2m compared to the previous year.

• Earnings before taxes fell by 18% to EUR 3.8m year-over-year.

Outlook and guidance

• Two new clinics with 180 treatment places are planned to open in Q2 2025, pending license approval.

• Revenue for 2025 is projected at around EUR 50m, with EBITDA expected between EUR 8-9m.

• New locations are anticipated to contribute positively to profits from 2026.